Review

human recombinant spp1 (MedChemExpress)

Name: human recombinant spp1
Brand: MedChemExpress
Rating: 94 (12 reviews)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress human recombinant spp1

High <t>SPP1</t> levels are linked to CRLM and immunotherapy resistance. A, Schematic diagram shows the construction of a CRLM cell line. B, Volcano plot of differentially expressed genes in the RNA-seq analysis of the LoVo and LoVo-HM cells. C, The GSE41568 , GSE14297 , GSE128213 , and LoVo-HM datasets were combined, identifying upregulated genes with a fold change >1.5 and P < 0.05. D, Venn diagram revealing SPP1 as the only gene upregulated in all datasets. E and F, Western blot analysis of SPP1 expression in primary tumors (P) and liver metastases (L) from five patients with colorectal cancer is shown as a heatmap ( E ) and in PDOs from three patients with colorectal cancer ( F ). G, ELISA measures SPP1 in the blood of 45 patients with colorectal cancer without metastasis (M0) and 46 with metastasis (M1). H, Imaging assessment before and after immunotherapy in a patient with colorectal cancer #1 with liver metastasis are shown, with tumor diameters analyzed ( n = 3 patients). I, Confocal microscopy to evaluate T-cell infiltration into the PDOs from patients with colorectal cancer ( n = 3 patients). Scale bar, 50 μm. J, Confocal microscopy shows T-cell cytotoxicity in PDOs of patients with colorectal cancer with propidium iodide (PI) labeling for dead cells, n = 3. Scale bar, 50 μm. K–M, Spatial transcriptomics revealing tumor regression and residual tumor regions ( n = 1). Spatial visualization of the cell types ( L ) and hierarchical clustering of the localized spots using Uniform Manifold Approximation and Projection (UMAP; M ). N and O, UMAP plots illustrating SPP1 expression in different cell clusters. P, mIHC examines SPP1 and TME in primary and liver metastases from five patients with colorectal cancer, with representative images. n = 5. Scale bar, 200 μm. Data are presented as mean ± SEM. Statistical analysis: two-tailed unpaired Student t test ( F , G , I , and J ) and paired-samples Student t test ( H and P ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; LM, liver metastasis; mIHC, multiplex IHC; PT, primary tumor.

Human Recombinant Spp1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant spp1/product/MedChemExpress
Average 94 stars, based on 12 article reviews

human recombinant spp1 - by Bioz Stars, 2026-02

94/100 stars

Images

1) Product Images from "SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts"

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

Journal: Cancer Research

doi: 10.1158/0008-5472.CAN-24-4916

High SPP1 levels are linked to CRLM and immunotherapy resistance. A, Schematic diagram shows the construction of a CRLM cell line. B, Volcano plot of differentially expressed genes in the RNA-seq analysis of the LoVo and LoVo-HM cells. C, The GSE41568 , GSE14297 , GSE128213 , and LoVo-HM datasets were combined, identifying upregulated genes with a fold change >1.5 and P < 0.05. D, Venn diagram revealing SPP1 as the only gene upregulated in all datasets. E and F, Western blot analysis of SPP1 expression in primary tumors (P) and liver metastases (L) from five patients with colorectal cancer is shown as a heatmap ( E ) and in PDOs from three patients with colorectal cancer ( F ). G, ELISA measures SPP1 in the blood of 45 patients with colorectal cancer without metastasis (M0) and 46 with metastasis (M1). H, Imaging assessment before and after immunotherapy in a patient with colorectal cancer #1 with liver metastasis are shown, with tumor diameters analyzed ( n = 3 patients). I, Confocal microscopy to evaluate T-cell infiltration into the PDOs from patients with colorectal cancer ( n = 3 patients). Scale bar, 50 μm. J, Confocal microscopy shows T-cell cytotoxicity in PDOs of patients with colorectal cancer with propidium iodide (PI) labeling for dead cells, n = 3. Scale bar, 50 μm. K–M, Spatial transcriptomics revealing tumor regression and residual tumor regions ( n = 1). Spatial visualization of the cell types ( L ) and hierarchical clustering of the localized spots using Uniform Manifold Approximation and Projection (UMAP; M ). N and O, UMAP plots illustrating SPP1 expression in different cell clusters. P, mIHC examines SPP1 and TME in primary and liver metastases from five patients with colorectal cancer, with representative images. n = 5. Scale bar, 200 μm. Data are presented as mean ± SEM. Statistical analysis: two-tailed unpaired Student t test ( F , G , I , and J ) and paired-samples Student t test ( H and P ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; LM, liver metastasis; mIHC, multiplex IHC; PT, primary tumor.

Figure Legend Snippet: High SPP1 levels are linked to CRLM and immunotherapy resistance. A, Schematic diagram shows the construction of a CRLM cell line. B, Volcano plot of differentially expressed genes in the RNA-seq analysis of the LoVo and LoVo-HM cells. C, The GSE41568 , GSE14297 , GSE128213 , and LoVo-HM datasets were combined, identifying upregulated genes with a fold change >1.5 and P < 0.05. D, Venn diagram revealing SPP1 as the only gene upregulated in all datasets. E and F, Western blot analysis of SPP1 expression in primary tumors (P) and liver metastases (L) from five patients with colorectal cancer is shown as a heatmap ( E ) and in PDOs from three patients with colorectal cancer ( F ). G, ELISA measures SPP1 in the blood of 45 patients with colorectal cancer without metastasis (M0) and 46 with metastasis (M1). H, Imaging assessment before and after immunotherapy in a patient with colorectal cancer #1 with liver metastasis are shown, with tumor diameters analyzed ( n = 3 patients). I, Confocal microscopy to evaluate T-cell infiltration into the PDOs from patients with colorectal cancer ( n = 3 patients). Scale bar, 50 μm. J, Confocal microscopy shows T-cell cytotoxicity in PDOs of patients with colorectal cancer with propidium iodide (PI) labeling for dead cells, n = 3. Scale bar, 50 μm. K–M, Spatial transcriptomics revealing tumor regression and residual tumor regions ( n = 1). Spatial visualization of the cell types ( L ) and hierarchical clustering of the localized spots using Uniform Manifold Approximation and Projection (UMAP; M ). N and O, UMAP plots illustrating SPP1 expression in different cell clusters. P, mIHC examines SPP1 and TME in primary and liver metastases from five patients with colorectal cancer, with representative images. n = 5. Scale bar, 200 μm. Data are presented as mean ± SEM. Statistical analysis: two-tailed unpaired Student t test ( F , G , I , and J ) and paired-samples Student t test ( H and P ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; LM, liver metastasis; mIHC, multiplex IHC; PT, primary tumor.

Techniques Used: RNA Sequencing, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Imaging, Confocal Microscopy, Labeling, Two Tailed Test, Multiplex Assay

SPP1 promotes the occurrence of colorectal cancer metastasis and immunotherapy resistance. A–C, The impact of SPP1 overexpression or knockdown on LoVo and LoVo-HM cell migration and invasion was assessed using transwell and wound healing assays. Scale bar, 100 μm. n = 3. D–F, Liver metastasis in C57BL/6J mice injected with MC38 cells was evaluated through tumor burden quantification and hematoxylin and eosin (H&E) staining ( n = 5 mice/group). Scale bar, 50 μm. G, Schematic representation of the in vivo experiment. CRC, colorectal cancer; LM, liver metastasis; PT, primary tumor. H, Flow cytometry confirmed human CD45 + (hCD45 + ) cell engraftment at 7 days after implantation ( n = 3 mice/group). I and J, Tumor morphology, weight, volume, and IFNγ expression were analyzed ( n = 3 mice/group). K–M, ELISA measured IFNγ ( K ), granzyme B ( L ), and SPP1 ( M ) levels in the tumor tissues ( n = 3 mice/group). N, Western blot analysis of SPP1 in the tumor tissues ( n = 3 mice/group). O, Hematoxylin and eosin analysis of the tumor tissues. P and Q, Masson trichrome staining and IHC were used to evaluate collagen content and αSMA expression. R and S, TUNEL and Ki-67 staining were performed on PDOX tumor tissues. Data are presented as mean ± SEM. P values were determined by two-tailed unpaired Student t test ( A , C , E , H–N , and P–S ) and one-way ANOVA ( B and C ). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; n.s., nonsignificant. IOD, integrated optical density.

Figure Legend Snippet: SPP1 promotes the occurrence of colorectal cancer metastasis and immunotherapy resistance. A–C, The impact of SPP1 overexpression or knockdown on LoVo and LoVo-HM cell migration and invasion was assessed using transwell and wound healing assays. Scale bar, 100 μm. n = 3. D–F, Liver metastasis in C57BL/6J mice injected with MC38 cells was evaluated through tumor burden quantification and hematoxylin and eosin (H&E) staining ( n = 5 mice/group). Scale bar, 50 μm. G, Schematic representation of the in vivo experiment. CRC, colorectal cancer; LM, liver metastasis; PT, primary tumor. H, Flow cytometry confirmed human CD45 + (hCD45 + ) cell engraftment at 7 days after implantation ( n = 3 mice/group). I and J, Tumor morphology, weight, volume, and IFNγ expression were analyzed ( n = 3 mice/group). K–M, ELISA measured IFNγ ( K ), granzyme B ( L ), and SPP1 ( M ) levels in the tumor tissues ( n = 3 mice/group). N, Western blot analysis of SPP1 in the tumor tissues ( n = 3 mice/group). O, Hematoxylin and eosin analysis of the tumor tissues. P and Q, Masson trichrome staining and IHC were used to evaluate collagen content and αSMA expression. R and S, TUNEL and Ki-67 staining were performed on PDOX tumor tissues. Data are presented as mean ± SEM. P values were determined by two-tailed unpaired Student t test ( A , C , E , H–N , and P–S ) and one-way ANOVA ( B and C ). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; n.s., nonsignificant. IOD, integrated optical density.

Techniques Used: Over Expression, Knockdown, Migration, Injection, Staining, In Vivo, Flow Cytometry, Expressing, Enzyme-linked Immunosorbent Assay, Western Blot, TUNEL Assay, Two Tailed Test

SPP1 enhances CAF infiltration into the TME and promotes their malignant phenotypes. A, Correlation analysis of SPP1 with key microenvironmental cells in TCGA datasets. DC, dendritic cell; MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell. B–E, Subcutaneous tumor models in the MC38 cells overexpressing SPP1 or a vector control were used to examine cell subpopulations via single-cell RNA-seq. UMAP, Uniform Manifold Approximation and Projection. F, Brightfield images of the CAFs and representative IHC staining images of CDX2, CK20, β-catenin, and Ki-67 in PDOs. H&E, hematoxylin and eosin. G–I, Transwell and wound healing assay of the CAFs with SPP1 overexpression or treatment ( n = 3). J, EdU assay for proliferation in CAFs with SPP1 overexpression or treatment. ( n = 3). K, Schematic representation of the collagen contraction assays. L, Collagen contraction assay with CAFs treated with or without SPP1 protein (1 µg/mL), n = 3. Data are presented as mean ± SEM. P values were determined using a two-tailed unpaired Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. CM, conditioned medium.

Figure Legend Snippet: SPP1 enhances CAF infiltration into the TME and promotes their malignant phenotypes. A, Correlation analysis of SPP1 with key microenvironmental cells in TCGA datasets. DC, dendritic cell; MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell. B–E, Subcutaneous tumor models in the MC38 cells overexpressing SPP1 or a vector control were used to examine cell subpopulations via single-cell RNA-seq. UMAP, Uniform Manifold Approximation and Projection. F, Brightfield images of the CAFs and representative IHC staining images of CDX2, CK20, β-catenin, and Ki-67 in PDOs. H&E, hematoxylin and eosin. G–I, Transwell and wound healing assay of the CAFs with SPP1 overexpression or treatment ( n = 3). J, EdU assay for proliferation in CAFs with SPP1 overexpression or treatment. ( n = 3). K, Schematic representation of the collagen contraction assays. L, Collagen contraction assay with CAFs treated with or without SPP1 protein (1 µg/mL), n = 3. Data are presented as mean ± SEM. P values were determined using a two-tailed unpaired Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. CM, conditioned medium.

Techniques Used: Derivative Assay, Plasmid Preparation, Control, RNA Sequencing, Immunohistochemistry, Wound Healing Assay, Over Expression, EdU Assay, Contraction Assay, Two Tailed Test

SPP1 promotes colorectal cancer metastasis through a positive feedback loop mediated by CAF-secreted CXCL12. A, Mass spectrometry analyzed supernatants from SPP1-stimulated and unstimulated CAFs, showing fold changes in secreted proteins (SPP1/control). B, A bubble chart displays commonly secreted protein levels in fibroblasts. C and D, Uniform Manifold Approximation and Projection (UMAP) plots and quantitative analysis reveal CXCL12 expression in fibroblasts within OE-SPP1 and vector groups. E, ELISA measured CXCL12 in CAF supernatants with/without SPP1 (1 µg/mL), n = 3. F, A flowchart shows CAF-conditioned medium’s (CM) impact on colorectal cancer (CRC) cell migration and invasion. G and H, Transwell and wound healing assays evaluated the effects of CAF-conditioned media or CXCL12-neutralizing antibody (100 ng/mL) on colorectal cancer cell migration and invasion ( n = 3). I–K, Flowchart illustrating the effects of CXCL12 or neutralizing antibody treatment on the colorectal cancer cell migration and invasion, assessed via transwell and wound healing assays ( n = 3). L, The effect of CXCL12 (100 ng/mL) or a neutralizing antibody (100 ng/mL) on the epithelial–mesenchymal transition markers expression in the colorectal cancer cells was analyzed using Western blotting ( n = 3). M, Correlation analysis of CXCL12 with SPP1 and TGFB1 in the TCGA dataset. N and O, The effect of CXCL12 (100 ng/mL) or neutralizing antibody (100 ng/mL) on the SPP1 and TGFβ expression in the colorectal cancer cells was evaluated using Western blotting ( N ) or ELISA ( O ), n = 3. Results are presented as mean ± SEM. P values were calculated using a two-tailed unpaired Student t test ( E ), whereas one-way ANOVA was used for the other comparisons. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Figure Legend Snippet: SPP1 promotes colorectal cancer metastasis through a positive feedback loop mediated by CAF-secreted CXCL12. A, Mass spectrometry analyzed supernatants from SPP1-stimulated and unstimulated CAFs, showing fold changes in secreted proteins (SPP1/control). B, A bubble chart displays commonly secreted protein levels in fibroblasts. C and D, Uniform Manifold Approximation and Projection (UMAP) plots and quantitative analysis reveal CXCL12 expression in fibroblasts within OE-SPP1 and vector groups. E, ELISA measured CXCL12 in CAF supernatants with/without SPP1 (1 µg/mL), n = 3. F, A flowchart shows CAF-conditioned medium’s (CM) impact on colorectal cancer (CRC) cell migration and invasion. G and H, Transwell and wound healing assays evaluated the effects of CAF-conditioned media or CXCL12-neutralizing antibody (100 ng/mL) on colorectal cancer cell migration and invasion ( n = 3). I–K, Flowchart illustrating the effects of CXCL12 or neutralizing antibody treatment on the colorectal cancer cell migration and invasion, assessed via transwell and wound healing assays ( n = 3). L, The effect of CXCL12 (100 ng/mL) or a neutralizing antibody (100 ng/mL) on the epithelial–mesenchymal transition markers expression in the colorectal cancer cells was analyzed using Western blotting ( n = 3). M, Correlation analysis of CXCL12 with SPP1 and TGFB1 in the TCGA dataset. N and O, The effect of CXCL12 (100 ng/mL) or neutralizing antibody (100 ng/mL) on the SPP1 and TGFβ expression in the colorectal cancer cells was evaluated using Western blotting ( N ) or ELISA ( O ), n = 3. Results are presented as mean ± SEM. P values were calculated using a two-tailed unpaired Student t test ( E ), whereas one-way ANOVA was used for the other comparisons. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Techniques Used: Mass Spectrometry, Control, Expressing, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Migration, Western Blot, Two Tailed Test

SPP1 inhibits T-cell infiltration and cytotoxicity via CXCL12 secretion from CAFs. A, Schematic of the coculture system with PDOs, T cells, and CAFs. CRC, colorectal cancer; E:T, effector to target. B and C, Confocal microscopy assessing the effect of SPP1 overexpression on T-cell infiltration and cytotoxicity in PDOs with or without CAFs ( n = 3). D and E, Impact of rhSPP1 (1 µg/mL) or CXCL12-neutralizing antibody (100 ng/mL) on T-cell infiltration and cytotoxicity in PDOs ( n = 3). Results are presented as mean ± SEM. P values were determined using one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., nonsignificant. PI, propidium iodide.

Figure Legend Snippet: SPP1 inhibits T-cell infiltration and cytotoxicity via CXCL12 secretion from CAFs. A, Schematic of the coculture system with PDOs, T cells, and CAFs. CRC, colorectal cancer; E:T, effector to target. B and C, Confocal microscopy assessing the effect of SPP1 overexpression on T-cell infiltration and cytotoxicity in PDOs with or without CAFs ( n = 3). D and E, Impact of rhSPP1 (1 µg/mL) or CXCL12-neutralizing antibody (100 ng/mL) on T-cell infiltration and cytotoxicity in PDOs ( n = 3). Results are presented as mean ± SEM. P values were determined using one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., nonsignificant. PI, propidium iodide.

Techniques Used: Confocal Microscopy, Over Expression

$SPP1 activates the β-catenin/HIF1α axis in the CAFs to drive CXCL12 secretion. A, Western blotting assessed key signaling pathway in CAFs after 24 hours of SPP1 protein stimulation. B–E, β-catenin and HIF1α expressions were analyzed following SPP1 or conditioned medium treatments, including from SPP1-overexpressing or -knockdown cells. F–H, HIF1α degradation was evaluated with MSAB or si-CTNNB1 transfection after cycloheximide (CHX) treatment, and HIF1α levels were measured after MSAB (1 µmol/L) or MG132 (20 µmol/L) pretreatment. I and J, Coimmunoprecipitation examined the HIF1α and β-catenin interaction. K and L, Immunofluorescence and nuclear–cytoplasmic fractionation assays assessed HIF1α and β-catenin localization ( n = 3). Scale bar, 25 μm. M–O, CXCL12 levels in conditioned media were measured after SPP1 (1 µg/mL) or MSAB treatments (24 hours). P, Correlation analysis of HIF1α and CXCL12 expression in 50 CAF samples using transcriptome data. Q, Dual-luciferase assays evaluated CXCL12 promoter activity ( n = 3). R and S, T-cell migration and infiltration were analyzed with or without SPP1 protein or MSAB treatment, n = 3. Scale bar, 50 μm. Western blotting ( A–J and L ) and ELISA ( M–O ) were repeated three times, with data representative of three independent experiments. Results are presented as mean ± SEM. P values were determined by one-way ANOVA ( M –O , R , and S ) and two-tailed unpaired Student t test ( F , G , and Q ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. R and S , Created with Figdraw.com .$
Figure Legend Snippet: SPP1 activates the β-catenin/HIF1α axis in the CAFs to drive CXCL12 secretion. A, Western blotting assessed key signaling pathway in CAFs after 24 hours of SPP1 protein stimulation. B–E, β-catenin and HIF1α expressions were analyzed following SPP1 or conditioned medium treatments, including from SPP1-overexpressing or -knockdown cells. F–H, HIF1α degradation was evaluated with MSAB or si-CTNNB1 transfection after cycloheximide (CHX) treatment, and HIF1α levels were measured after MSAB (1 µmol/L) or MG132 (20 µmol/L) pretreatment. I and J, Coimmunoprecipitation examined the HIF1α and β-catenin interaction. K and L, Immunofluorescence and nuclear–cytoplasmic fractionation assays assessed HIF1α and β-catenin localization ( n = 3). Scale bar, 25 μm. M–O, CXCL12 levels in conditioned media were measured after SPP1 (1 µg/mL) or MSAB treatments (24 hours). P, Correlation analysis of HIF1α and CXCL12 expression in 50 CAF samples using transcriptome data. Q, Dual-luciferase assays evaluated CXCL12 promoter activity ( n = 3). R and S, T-cell migration and infiltration were analyzed with or without SPP1 protein or MSAB treatment, n = 3. Scale bar, 50 μm. Western blotting ( A–J and L ) and ELISA ( M–O ) were repeated three times, with data representative of three independent experiments. Results are presented as mean ± SEM. P values were determined by one-way ANOVA ( M –O , R , and S ) and two-tailed unpaired Student t test ( F , G , and Q ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. R and S , Created with Figdraw.com .

Techniques Used: Western Blot, Knockdown, Transfection, Immunofluorescence, Fractionation, Expressing, Luciferase, Activity Assay, Migration, Enzyme-linked Immunosorbent Assay, Two Tailed Test

Talabostat mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.

Figure Legend Snippet: Talabostat mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.

Techniques Used: Enzyme-linked Immunosorbent Assay, Staining

Blocking the SPP1/CXCL12 axis alleviates immunosuppression in the liver microenvironment and augments the benefits of immunotherapy. A, Flowchart of the intrasplenic injection model of liver metastasis using OE-SPP1 MC38 cells ( i.s.v. , intrasplenic injection; i.p. , intraperitoneal injection). B–D, Representative tumor morphology, hematoxylin and eosin staining, liver weight, and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. E and F, Flow cytometric analysis of IFNγ + CD8 + and GZMB + CD8 + T cells in liver metastases ( n = 5 mice/group). G, Flowchart of the cecal orthotopic injection model of liver metastasis in the NOG mice using HCT116-HM cells. H and I, Luciferase images and bioluminescence quantification of metastatic livers. J, Hematoxylin and eosin staining and the number of liver metastases ( n = 5 mice/group). K, ELISA analysis of IFNγ levels in liver metastases ( n = 5 mice/group). L–N, ELISA of SPP1 and CXCL12 in peripheral blood of responders ( n = 25) and nonresponders ( n = 12) in immunotherapy-treated colorectal cancer cohorts. O, Diagram of tumor-derived SPP1 activation of CAFs to promote immunotherapy resistance in CRLM. Data are presented as mean ± SEM. P values were determined using one-way ANOVA ( C–F , and I–K ) and two-tailed unpaired Student t test ( L and M ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. O, Created in BioRender. Liu, F. (2025) https://BioRender.com/k7tx8am .

Figure Legend Snippet: Blocking the SPP1/CXCL12 axis alleviates immunosuppression in the liver microenvironment and augments the benefits of immunotherapy. A, Flowchart of the intrasplenic injection model of liver metastasis using OE-SPP1 MC38 cells ( i.s.v. , intrasplenic injection; i.p. , intraperitoneal injection). B–D, Representative tumor morphology, hematoxylin and eosin staining, liver weight, and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. E and F, Flow cytometric analysis of IFNγ + CD8 + and GZMB + CD8 + T cells in liver metastases ( n = 5 mice/group). G, Flowchart of the cecal orthotopic injection model of liver metastasis in the NOG mice using HCT116-HM cells. H and I, Luciferase images and bioluminescence quantification of metastatic livers. J, Hematoxylin and eosin staining and the number of liver metastases ( n = 5 mice/group). K, ELISA analysis of IFNγ levels in liver metastases ( n = 5 mice/group). L–N, ELISA of SPP1 and CXCL12 in peripheral blood of responders ( n = 25) and nonresponders ( n = 12) in immunotherapy-treated colorectal cancer cohorts. O, Diagram of tumor-derived SPP1 activation of CAFs to promote immunotherapy resistance in CRLM. Data are presented as mean ± SEM. P values were determined using one-way ANOVA ( C–F , and I–K ) and two-tailed unpaired Student t test ( L and M ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. O, Created in BioRender. Liu, F. (2025) https://BioRender.com/k7tx8am .

Techniques Used: Blocking Assay, Injection, Staining, Luciferase, Enzyme-linked Immunosorbent Assay, Derivative Assay, Activation Assay, Two Tailed Test

Image Search Results

Journal: Cancer Research

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

doi: 10.1158/0008-5472.CAN-24-4916

Figure Lengend Snippet: High SPP1 levels are linked to CRLM and immunotherapy resistance. A, Schematic diagram shows the construction of a CRLM cell line. B, Volcano plot of differentially expressed genes in the RNA-seq analysis of the LoVo and LoVo-HM cells. C, The GSE41568 , GSE14297 , GSE128213 , and LoVo-HM datasets were combined, identifying upregulated genes with a fold change >1.5 and P < 0.05. D, Venn diagram revealing SPP1 as the only gene upregulated in all datasets. E and F, Western blot analysis of SPP1 expression in primary tumors (P) and liver metastases (L) from five patients with colorectal cancer is shown as a heatmap ( E ) and in PDOs from three patients with colorectal cancer ( F ). G, ELISA measures SPP1 in the blood of 45 patients with colorectal cancer without metastasis (M0) and 46 with metastasis (M1). H, Imaging assessment before and after immunotherapy in a patient with colorectal cancer #1 with liver metastasis are shown, with tumor diameters analyzed ( n = 3 patients). I, Confocal microscopy to evaluate T-cell infiltration into the PDOs from patients with colorectal cancer ( n = 3 patients). Scale bar, 50 μm. J, Confocal microscopy shows T-cell cytotoxicity in PDOs of patients with colorectal cancer with propidium iodide (PI) labeling for dead cells, n = 3. Scale bar, 50 μm. K–M, Spatial transcriptomics revealing tumor regression and residual tumor regions ( n = 1). Spatial visualization of the cell types ( L ) and hierarchical clustering of the localized spots using Uniform Manifold Approximation and Projection (UMAP; M ). N and O, UMAP plots illustrating SPP1 expression in different cell clusters. P, mIHC examines SPP1 and TME in primary and liver metastases from five patients with colorectal cancer, with representative images. n = 5. Scale bar, 200 μm. Data are presented as mean ± SEM. Statistical analysis: two-tailed unpaired Student t test ( F , G , I , and J ) and paired-samples Student t test ( H and P ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. CRC, colorectal cancer; LM, liver metastasis; mIHC, multiplex IHC; PT, primary tumor.

Article Snippet: Human recombinant SPP1 (HY- P70499 ) and CXCL12 (HY- P70469 ) proteins were obtained from MedChemExpress.

Techniques: RNA Sequencing, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Imaging, Confocal Microscopy, Labeling, Two Tailed Test, Multiplex Assay

Journal: Cancer Research

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

doi: 10.1158/0008-5472.CAN-24-4916

Figure Lengend Snippet: SPP1 promotes the occurrence of colorectal cancer metastasis and immunotherapy resistance. A–C, The impact of SPP1 overexpression or knockdown on LoVo and LoVo-HM cell migration and invasion was assessed using transwell and wound healing assays. Scale bar, 100 μm. n = 3. D–F, Liver metastasis in C57BL/6J mice injected with MC38 cells was evaluated through tumor burden quantification and hematoxylin and eosin (H&E) staining ( n = 5 mice/group). Scale bar, 50 μm. G, Schematic representation of the in vivo experiment. CRC, colorectal cancer; LM, liver metastasis; PT, primary tumor. H, Flow cytometry confirmed human CD45 + (hCD45 + ) cell engraftment at 7 days after implantation ( n = 3 mice/group). I and J, Tumor morphology, weight, volume, and IFNγ expression were analyzed ( n = 3 mice/group). K–M, ELISA measured IFNγ ( K ), granzyme B ( L ), and SPP1 ( M ) levels in the tumor tissues ( n = 3 mice/group). N, Western blot analysis of SPP1 in the tumor tissues ( n = 3 mice/group). O, Hematoxylin and eosin analysis of the tumor tissues. P and Q, Masson trichrome staining and IHC were used to evaluate collagen content and αSMA expression. R and S, TUNEL and Ki-67 staining were performed on PDOX tumor tissues. Data are presented as mean ± SEM. P values were determined by two-tailed unpaired Student t test ( A , C , E , H–N , and P–S ) and one-way ANOVA ( B and C ). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; n.s., nonsignificant. IOD, integrated optical density.

Article Snippet: Human recombinant SPP1 (HY- P70499 ) and CXCL12 (HY- P70469 ) proteins were obtained from MedChemExpress.

Techniques: Over Expression, Knockdown, Migration, Injection, Staining, In Vivo, Flow Cytometry, Expressing, Enzyme-linked Immunosorbent Assay, Western Blot, TUNEL Assay, Two Tailed Test

Journal: Cancer Research

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

doi: 10.1158/0008-5472.CAN-24-4916

Figure Lengend Snippet: SPP1 enhances CAF infiltration into the TME and promotes their malignant phenotypes. A, Correlation analysis of SPP1 with key microenvironmental cells in TCGA datasets. DC, dendritic cell; MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell. B–E, Subcutaneous tumor models in the MC38 cells overexpressing SPP1 or a vector control were used to examine cell subpopulations via single-cell RNA-seq. UMAP, Uniform Manifold Approximation and Projection. F, Brightfield images of the CAFs and representative IHC staining images of CDX2, CK20, β-catenin, and Ki-67 in PDOs. H&E, hematoxylin and eosin. G–I, Transwell and wound healing assay of the CAFs with SPP1 overexpression or treatment ( n = 3). J, EdU assay for proliferation in CAFs with SPP1 overexpression or treatment. ( n = 3). K, Schematic representation of the collagen contraction assays. L, Collagen contraction assay with CAFs treated with or without SPP1 protein (1 µg/mL), n = 3. Data are presented as mean ± SEM. P values were determined using a two-tailed unpaired Student t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. CM, conditioned medium.

Article Snippet: Human recombinant SPP1 (HY- P70499 ) and CXCL12 (HY- P70469 ) proteins were obtained from MedChemExpress.

Techniques: Derivative Assay, Plasmid Preparation, Control, RNA Sequencing, Immunohistochemistry, Wound Healing Assay, Over Expression, EdU Assay, Contraction Assay, Two Tailed Test

Journal: Cancer Research

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

doi: 10.1158/0008-5472.CAN-24-4916

Figure Lengend Snippet: SPP1 promotes colorectal cancer metastasis through a positive feedback loop mediated by CAF-secreted CXCL12. A, Mass spectrometry analyzed supernatants from SPP1-stimulated and unstimulated CAFs, showing fold changes in secreted proteins (SPP1/control). B, A bubble chart displays commonly secreted protein levels in fibroblasts. C and D, Uniform Manifold Approximation and Projection (UMAP) plots and quantitative analysis reveal CXCL12 expression in fibroblasts within OE-SPP1 and vector groups. E, ELISA measured CXCL12 in CAF supernatants with/without SPP1 (1 µg/mL), n = 3. F, A flowchart shows CAF-conditioned medium’s (CM) impact on colorectal cancer (CRC) cell migration and invasion. G and H, Transwell and wound healing assays evaluated the effects of CAF-conditioned media or CXCL12-neutralizing antibody (100 ng/mL) on colorectal cancer cell migration and invasion ( n = 3). I–K, Flowchart illustrating the effects of CXCL12 or neutralizing antibody treatment on the colorectal cancer cell migration and invasion, assessed via transwell and wound healing assays ( n = 3). L, The effect of CXCL12 (100 ng/mL) or a neutralizing antibody (100 ng/mL) on the epithelial–mesenchymal transition markers expression in the colorectal cancer cells was analyzed using Western blotting ( n = 3). M, Correlation analysis of CXCL12 with SPP1 and TGFB1 in the TCGA dataset. N and O, The effect of CXCL12 (100 ng/mL) or neutralizing antibody (100 ng/mL) on the SPP1 and TGFβ expression in the colorectal cancer cells was evaluated using Western blotting ( N ) or ELISA ( O ), n = 3. Results are presented as mean ± SEM. P values were calculated using a two-tailed unpaired Student t test ( E ), whereas one-way ANOVA was used for the other comparisons. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Article Snippet: Human recombinant SPP1 (HY- P70499 ) and CXCL12 (HY- P70469 ) proteins were obtained from MedChemExpress.

Techniques: Mass Spectrometry, Control, Expressing, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Migration, Western Blot, Two Tailed Test

Journal: Cancer Research

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

doi: 10.1158/0008-5472.CAN-24-4916

Figure Lengend Snippet: SPP1 inhibits T-cell infiltration and cytotoxicity via CXCL12 secretion from CAFs. A, Schematic of the coculture system with PDOs, T cells, and CAFs. CRC, colorectal cancer; E:T, effector to target. B and C, Confocal microscopy assessing the effect of SPP1 overexpression on T-cell infiltration and cytotoxicity in PDOs with or without CAFs ( n = 3). D and E, Impact of rhSPP1 (1 µg/mL) or CXCL12-neutralizing antibody (100 ng/mL) on T-cell infiltration and cytotoxicity in PDOs ( n = 3). Results are presented as mean ± SEM. P values were determined using one-way ANOVA. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., nonsignificant. PI, propidium iodide.

Article Snippet: Human recombinant SPP1 (HY- P70499 ) and CXCL12 (HY- P70469 ) proteins were obtained from MedChemExpress.

Techniques: Confocal Microscopy, Over Expression

Journal: Cancer Research

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

doi: 10.1158/0008-5472.CAN-24-4916

Figure Lengend Snippet: SPP1 activates the β-catenin/HIF1α axis in the CAFs to drive CXCL12 secretion. A, Western blotting assessed key signaling pathway in CAFs after 24 hours of SPP1 protein stimulation. B–E, β-catenin and HIF1α expressions were analyzed following SPP1 or conditioned medium treatments, including from SPP1-overexpressing or -knockdown cells. F–H, HIF1α degradation was evaluated with MSAB or si-CTNNB1 transfection after cycloheximide (CHX) treatment, and HIF1α levels were measured after MSAB (1 µmol/L) or MG132 (20 µmol/L) pretreatment. I and J, Coimmunoprecipitation examined the HIF1α and β-catenin interaction. K and L, Immunofluorescence and nuclear–cytoplasmic fractionation assays assessed HIF1α and β-catenin localization ( n = 3). Scale bar, 25 μm. M–O, CXCL12 levels in conditioned media were measured after SPP1 (1 µg/mL) or MSAB treatments (24 hours). P, Correlation analysis of HIF1α and CXCL12 expression in 50 CAF samples using transcriptome data. Q, Dual-luciferase assays evaluated CXCL12 promoter activity ( n = 3). R and S, T-cell migration and infiltration were analyzed with or without SPP1 protein or MSAB treatment, n = 3. Scale bar, 50 μm. Western blotting ( A–J and L ) and ELISA ( M–O ) were repeated three times, with data representative of three independent experiments. Results are presented as mean ± SEM. P values were determined by one-way ANOVA ( M –O , R , and S ) and two-tailed unpaired Student t test ( F , G , and Q ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. R and S , Created with Figdraw.com .

Article Snippet: Human recombinant SPP1 (HY- P70499 ) and CXCL12 (HY- P70469 ) proteins were obtained from MedChemExpress.

Techniques: Western Blot, Knockdown, Transfection, Immunofluorescence, Fractionation, Expressing, Luciferase, Activity Assay, Migration, Enzyme-linked Immunosorbent Assay, Two Tailed Test

Journal: Cancer Research

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

doi: 10.1158/0008-5472.CAN-24-4916

Figure Lengend Snippet: Talabostat mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.

Article Snippet: Human recombinant SPP1 (HY- P70499 ) and CXCL12 (HY- P70469 ) proteins were obtained from MedChemExpress.

Techniques: Enzyme-linked Immunosorbent Assay, Staining

Journal: Cancer Research

Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

doi: 10.1158/0008-5472.CAN-24-4916

Figure Lengend Snippet: Blocking the SPP1/CXCL12 axis alleviates immunosuppression in the liver microenvironment and augments the benefits of immunotherapy. A, Flowchart of the intrasplenic injection model of liver metastasis using OE-SPP1 MC38 cells ( i.s.v. , intrasplenic injection; i.p. , intraperitoneal injection). B–D, Representative tumor morphology, hematoxylin and eosin staining, liver weight, and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. E and F, Flow cytometric analysis of IFNγ + CD8 + and GZMB + CD8 + T cells in liver metastases ( n = 5 mice/group). G, Flowchart of the cecal orthotopic injection model of liver metastasis in the NOG mice using HCT116-HM cells. H and I, Luciferase images and bioluminescence quantification of metastatic livers. J, Hematoxylin and eosin staining and the number of liver metastases ( n = 5 mice/group). K, ELISA analysis of IFNγ levels in liver metastases ( n = 5 mice/group). L–N, ELISA of SPP1 and CXCL12 in peripheral blood of responders ( n = 25) and nonresponders ( n = 12) in immunotherapy-treated colorectal cancer cohorts. O, Diagram of tumor-derived SPP1 activation of CAFs to promote immunotherapy resistance in CRLM. Data are presented as mean ± SEM. P values were determined using one-way ANOVA ( C–F , and I–K ) and two-tailed unpaired Student t test ( L and M ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. O, Created in BioRender. Liu, F. (2025) https://BioRender.com/k7tx8am .

Article Snippet: Human recombinant SPP1 (HY- P70499 ) and CXCL12 (HY- P70469 ) proteins were obtained from MedChemExpress.

Techniques: Blocking Assay, Injection, Staining, Luciferase, Enzyme-linked Immunosorbent Assay, Derivative Assay, Activation Assay, Two Tailed Test

Characterization of ligament immune compartment and possible pathogenic role of SPP1 + macrophages. (a) UMAP plot of immune cells in spinal ligament tissues. (b) Inflammation scores of the main immune cell lineages in ligament. (c) UMAP plot of monocytes and macrophages in spinal ligament tissues. (d) Hierarchical clustering of DEGs in monocytes and macrophages. (e) Pseudo‐time analysis of monocyte and macrophage subpopulations. (f) Pathway enrichment analysis for DEGs of macrophages from ligament tissues. (g) Ligand–receptor interactions between macrophages and other cell types. (h–j) Quantitative PCR assays (h) and western blot analysis (i, j) of control cultured primary ligament cells and those treated with short interfering RNA targeting ATF3 and recombinant SPP1. *, p ‐value < 0.05; **, p ‐value < 0.01; ***, p ‐value < 0.001.

Journal: Aging Cell

Article Title: Single‐cell RNA sequencing reveals the CRTAC1 + population actively contributes to the pathogenesis of spinal ligament degeneration by SPP1 + macrophage

doi: 10.1111/acel.14320

Figure Lengend Snippet: Characterization of ligament immune compartment and possible pathogenic role of SPP1 + macrophages. (a) UMAP plot of immune cells in spinal ligament tissues. (b) Inflammation scores of the main immune cell lineages in ligament. (c) UMAP plot of monocytes and macrophages in spinal ligament tissues. (d) Hierarchical clustering of DEGs in monocytes and macrophages. (e) Pseudo‐time analysis of monocyte and macrophage subpopulations. (f) Pathway enrichment analysis for DEGs of macrophages from ligament tissues. (g) Ligand–receptor interactions between macrophages and other cell types. (h–j) Quantitative PCR assays (h) and western blot analysis (i, j) of control cultured primary ligament cells and those treated with short interfering RNA targeting ATF3 and recombinant SPP1. *, p ‐value < 0.05; **, p ‐value < 0.01; ***, p ‐value < 0.001.

Article Snippet: For recombinant protein stimulation experiments, primary human ligament cells from patients with traumatic injury were incubated with 200 ng/mL recombinant SPP1 protein (1433‐OP‐050, R&D Systems, USA).

Techniques: Real-time Polymerase Chain Reaction, Western Blot, Control, Cell Culture, Small Interfering RNA, Recombinant

Review

Structured Review

Images

1) Product Images from "SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts"

Similar Products

Image Search Results